Rethink Head Lice Treatment.

louse-climb

Explore the Latest Guidance

Resolve The Lice Cycle With Natroba™

louse-climb2

Take Decisive Action

No known resistance to spinosad in head lice<sup>2</sup>

No known resistance to spinosad in head lice2

Find Natroba™ Near You

Formulary & Pharmacy Lookup tools for immediate access to insurance and product availability information.

Connect with a Rep

Request a visit and a Natroba™ rep will share the evidence-based product information in person with you and your staff.

Nix® is a registered trademark of Prestige Brands, Inc.

 

References

  1. Stough D, Shellabarger S, Quiring J, Gabrielsen A. Efficacy and safety of spinosad and permethrin crème rinses for pediculosis capitis (head lice). Pediatrics. 2009;124(3): e389-395.
  2. DOW AgroSciences 2001.
  3. Natroba Prescribing Information
  4. Data on file.

NAT-RRW1-000

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.